Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index; 2 of the 14 sources its claims cite were checked for support.

Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization

Open access

Abstract

BACKGROUND: WHO, as requested by its member states, launched the Expanded Programme on Immunization (EPI) in 1974 to make life-saving vaccines available to all globally. To mark the 50-year anniversary of EPI, we sought to quantify the public health impact of vaccination globally since the programme's inception. METHODS: In this modelling study, we used a suite of mathematical and statistical models to estimate the global and regional public health impact of 50 years of vaccination against 14 pathogens in EPI. For the modelled pathogens, we considered coverage of all routine and supplementary vaccines delivered since 1974 and estimated the mortality and morbidity averted for each age cohort relative to a hypothetical scenario of no historical vaccination. We then used these modelled outcomes to estimate the contribution of vaccination to globally declining infant and child mortality rates over this period. FINDINGS: Since 1974, vaccination has averted 154 million deaths, including 146 million among children younger than 5 years of whom 101 million were infants younger than 1 year. For every death averted, 66 years of full health were gained on average, translating to 10·2 billion years of full health gained. We estimate that vaccination has accounted for 40% of the observed decline in global infant mortality, 52% in the African region. In 2024, a child younger than 10 years is 40% more likely to survive to their next birthday relative to a hypothetical scenario of no historical vaccination. Increased survival probability is observed even well into late adulthood. INTERPRETATION: Since 1974 substantial gains in childhood survival have occurred in every global region. We estimate that EPI has provided the single greatest contribution to improved infant survival over the past 50 years. In the context of strengthening primary health care, our results show that equitable universal access to immunisation remains crucial to sustain health gains and continue to save future lives from preventable infectious mortality. FUNDING: WHO.

Overview

CoChat Summary

TL;DR

Modelling 50 years of the WHO Expanded Programme on Immunization estimates that vaccination against 14 pathogens averted 154 million deaths from 1974 to 2024, including 146 million in children younger than 5 years, and gained 10·2 billion years of full health. Vaccination accounted for 40% of the global decline in infant mortality, with measles vaccination the single greatest contributor.

Key findings

  • Vaccination averted 154 million deaths, including 146 million in children younger than 5 years and 101 million in infants younger than 1 year; 9·0 billion life-years and 10·2 billion years of full health were gained. For each death averted, an average of 58 years of life and 66 years of full health were gained.
  • Measles vaccination accounted for 93·7 million lives saved (60·8%) of the 154·0 million total. Poliomyelitis vaccination averted 1% of deaths but accounted for 0·8 billion (7·8%) of the 10·2 billion years of full health gained.
  • Vaccination was estimated to be directly responsible for 40% of the global decline in infant mortality, varying from 21% in the Western Pacific region to 52% in the African region. In 2024, children aged 10 years were approximately 44% more likely to survive to their next birthday than with no historical vaccination; individuals aged 25 years were 35% more likely, and those aged 50 years were 16% more likely.
  • Global coverage with a third dose of diphtheria–tetanus–pertussis vaccine increased from less than 5% in 1974 to 86% in 2019 before the COVID-19 pandemic, and was 84% at the time of the study.

Methods

  • Modelling study estimating deaths averted, life-years gained, and years of full health gained from vaccination against 14 pathogens in 194 WHO member states between June 1, 1974, and May 31, 2024, through routine and supplementary immunisation activities, relative to a hypothetical scenario of no historical vaccination.
  • The analysis synthesised results of 22 models using three modelling forms: dynamic transmission models for measles and poliomyelitis; extended Vaccine Impact Modelling Consortium transmission models for *H influenzae* type B, hepatitis B, Japanese encephalitis, invasive pneumococcal disease, rotavirus, and rubella; and upgraded static disease burden models for diphtheria, tetanus, pertussis, and tuberculosis. Age-specific coverage was drawn from WHO Immunization dashboard, WHO Supplementary Immunization Activities Database, WHO Polio Information System, and VIMC estimates; 24 vaccine activities were evaluated.
  • Regression-based imputation and functional fitting with Markov chain Monte Carlo and Akaike Information Criterion model selection were used to extrapolate impact to countries and time periods without direct model estimates. Primary outcomes were deaths averted, years of life gained, years of full health gained, and the proportion of infant mortality reduction attributable to vaccination, with secondary evaluation by WHO region and World Bank income stratum.

Limitations

  • The paper states that the calendar-year approach does not fully account for post-2024 lifetime vaccination impacts, implying a substantial underestimate for diseases such as hepatitis B; HPV was excluded because of incomparability of timeframe. The analysis also excludes vaccines against COVID-19, influenza, HPV, outbreak vaccines such as cholera or Ebola, vaccines targeting disease in adult life, and vaccines used largely in high-income settings such as varicella, herpes zoster, or mumps; the counterfactual assumed a smallpox-free world, so smallpox eradication benefits were not counted.
  • The paper states that double counting is a limitation but estimates it would have only a small (0·01%) effect; findings are presented at global and regional resolution, limiting geographical conclusions; uncertainty propagation was not possible for all hierarchical models or inputs; and posterior credible intervals had arbitrarily predefined widths and should not be interpreted as bounds for final outcomes.
  • The text makes evident further limitations: the authors describe the analysis as a minimum conservative estimate because it excludes possible heterologous or non-specific vaccine effects, downstream effects on non-communicable disease mortality, and broader economic or community development gains. The text also contains an internal numerical inconsistency, reporting 10·2 billion years of full health in the abstract and results but referring later to 10·8 billion healthy life-years gained.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(24)00850-x

Cites

13 of 14 references verified1 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Deaths averted, years of life saved, and years of full health gained due to vaccination Data are cumulative 1974–2024. Measles: deaths averted: 93·7 million; years of life saved: 5·7 billion; years of full health gained: 5·8 billion. Tetanus: deaths averted: 27·9 million; years of life saved: 1·4 billion; years of full health gained: 1·4 billion. Pertussis: deaths averted: 13·2 million; years of life saved: 0·8 billion; years of full health gained: 1 billion. Tuberculosis: deaths averted: 10·9 million; years of life saved: 0·6 billion; years of full health gained: 0·9 billion. Haemophilus influenzae type B: deaths averted: 2·8 million; years of life saved: 0·2 billion; years of full health gained: 0·2 billion. Poliomyelitis: deaths averted: 1·6 million; years of life saved: 0·1 billion; years of full health gained: 0·8 billion. Other diseases: deaths averted: 3·8 million; years of life saved: 0·2 billion; years of full health gained: 0·3 billion.
Figure 1 Deaths averted, years of life saved, and years of full health gained due to vaccination Data are cumulative 1974–2024. Measles: deaths averted: 93·7 million; years of life saved: 5·7 billion; years of full health gained: 5·8 billion. Tetanus: deaths averted: 27·9 million; years of life saved: 1·4 billion; years of full health gained: 1·4 billion. Pertussis: deaths averted: 13·2 million; years of life saved: 0·8 billion; years of full health gained: 1 billion. Tuberculosis: deaths averted: 10·9 million; years of life saved: 0·6 billion; years of full health gained: 0·9 billion. Haemophilus influenzae type B: deaths averted: 2·8 million; years of life saved: 0·2 billion; years of full health gained: 0·2 billion. Poliomyelitis: deaths averted: 1·6 million; years of life saved: 0·1 billion; years of full health gained: 0·8 billion. Other diseases: deaths averted: 3·8 million; years of life saved: 0·2 billion; years of full health gained: 0·3 billion.CC BY · PubMed Central
Figure 2 Infant mortality 1974–2024, the proportional effect of vaccination on overall decreasing trends, and global vaccine coverage DTP=diphtheria–tetanus–pertussis. PCV=pneumococcal conjugate vaccine.
Figure 2 Infant mortality 1974–2024, the proportional effect of vaccination on overall decreasing trends, and global vaccine coverage DTP=diphtheria–tetanus–pertussis. PCV=pneumococcal conjugate vaccine.CC BY · PubMed Central
Figure 3 Marginal increase in survival probability in 2024 by year of life and WHO Region, compared with the hypothetical scenario of no historical vaccination Relative represents proportional percent change in this baseline risk. Absolute represents percentage point reduction in 2024 risk of death for the next year for a person of a given age. (A) Relative marginal increase in survival probability in 2024. (B) Absolute marginal increase in survival probability in 2024.
Figure 3 Marginal increase in survival probability in 2024 by year of life and WHO Region, compared with the hypothetical scenario of no historical vaccination Relative represents proportional percent change in this baseline risk. Absolute represents percentage point reduction in 2024 risk of death for the next year for a person of a given age. (A) Relative marginal increase in survival probability in 2024. (B) Absolute marginal increase in survival probability in 2024.CC BY · PubMed Central

Verification

Claims the paper makes

2 Valid · 2 Not valid · 8 Not checked · 77 Own results and interpretations

48 more claims

Create a free account to see all 89 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 23
  • It may state two separate claims as one. 20

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 12 references

Cited by

See all 655

Metadata

Authors
Shattock, A. J., Johnson, H. C., Sim, S. Y., Carter, A., Lambach, P., Hutubessy, R. C. W., Thompson, K. M., Badizadegan, K., Lambert, B., Ferrari, M. J., Jit, M., Fu, H., Silal, S. P., Hounsell, R. A., White, R. G., Mosser, J. F., Gaythorpe, K. A. M., Trotter, C. L., Lindstrand, A., O'Brien, K. L., & Bar-Zeev, N.
Affiliations
  • Swiss Tropical and Public Health Institute (CH)
  • University of Cambridge (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Washington (US)
  • Pennsylvania State University (US)
  • University of Cape Town (ZA)
Venue
The Lancet
Publisher
Elsevier BV
Published
2024-05
Volume
403
Issue
10441
Pages
2307-2316
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4396571207
Cited by
655
References
12
Citations by year
2026: 324 · 2025: 268 · 2024: 63
FWCI
295.47
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • London School of Economics and Political Science Research Online (London School of Economics and Political Science) (acceptedVersion)
  • London School of Economics and Political Science Theses Online (London School of Economics and Political Science) (acceptedVersion)
  • LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
Funders
  • World Health Organization (201910)
  • Bill and Melinda Gates Foundation (OPP1157270, INV-034218, INV-009125)
Topics
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Global Maternal and Child Health
  • Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Keywords
Expanded Programme on Immunization, vaccine impact, mortality averted, child mortality decline, infant mortality, life-years gained, child survival, vaccination coverage, global health impact
MeSH terms
Adolescent, Adult, Child, Child, Preschool, Humans, Infant, Infant Mortality, Infant, Newborn, Middle Aged, Public Health, Vaccination, Global Health, Models, Statistical, Immunization Programs, Child Mortality, History, 20th Century, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00850-x
The paper
Shattock, A. J., Johnson, H. C., Sim, S. Y., Carter, A., Lambach, P., Hutubessy, R. C. W., Thompson, K. M., Badizadegan, K., Lambert, B., Ferrari, M. J., Jit, M., Fu, H., Silal, S. P., Hounsell, R. A., White, R. G., Mosser, J. F., Gaythorpe, K. A. M., Trotter, C. L., Lindstrand, A., . . . Bar-Zeev, N. (2024). Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. The Lancet. https://doi.org/10.1016/s0140-6736(24)00850-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.